Advertisement
Screener

CURAXIS PHARMACEUTICAL CORP Quick Ratio

CURAXIS PHARMACEUTICAL CORP Quick Ratio

  • Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2012-03-31..

Quick ratio

Overview →

Financial period ending 2012-03-31; current quote (m). Amounts retain their stated periods and units.

MetricValueFormula and calculation
Quick ratio · latest quarter(m)Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2012-03-31.

Calculation unavailable: missing inputs remain (m).

Calculation inputs

InputAmount with unitRaw financial data
Cash, securities and trade receivables(m)Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current
Current obligations6.85M USDLiabilities, Current
Cash and equivalents11.00K USDCash and Cash Equivalents, at Carrying Value
Short-term securities(m)
Customer receivables(m)Accounts Receivable, after Allowance for Credit Loss, Current
Inventory · excluded from quick assets(m)

Calculated history

Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.

Period endingCash, securities and trade receivables (USD)Current obligations (USD)Cash and equivalents (USD)Short-term securities (USD)Customer receivables (USD)Inventory · excluded from quick assets (USD)Quick ratio
2012-03-31(m)$6.85M$11.00K(m)(m)(m)(m)
2011-12-31(m)$6.59M$22.00K(m)(m)(m)(m)
2011-09-30(m)$8.52M$72.00K(m)$0.00(m)(m)
2011-06-30(m)$8.29M$9.00M(m)$0.00(m)(m)
2011-03-31(m)(m)$9.00K(m)(m)(m)(m)
2010-12-31(m)(m)(m)(m)$0.00(m)(m)
2010-09-30(m)(m)$273.00K(m)(m)(m)(m)
2010-06-30(m)(m)$79.00K(m)(m)(m)(m)
2009-12-31(m)(m)$631.00K(m)(m)(m)(m)

(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.